Genetically proxied PCSK9 inhibition is associated with reduced psoriatic arthritis risk.

ABSTRACT:

Background

Lipid pathways play a crucial role in psoriatic arthritis development, and some lipid-lowering drugs are believed to have therapeutic benefits due to their anti-inflammatory properties. Traditional observational studies face issues with confounding factors, complicating the interpretation of causality. This study seeks to determine the genetic link between these medications and the risk of psoriatic arthritis.

Methods

This drug target study utilized the Mendelian randomization strategy. We harnessed high-quality data from population-level genome-wide association studies sourced from the UK Biobank and FinnGen databases. The inverse variance-weighted method, complemented by robust pleiotropy methods, was employed. We examined the causal relationships between three

SUBMITTER: Li J 

PROVIDER: S-EPMC10894168 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature